&NA;Sampatrilat (UK 81252) is a potent dual inhibitor of neutral endopeptidase and ACE being developed by Pfizer. Roberts Pharmaceuticals has acquired an exclusive licensing rights from Pfizer to develop and market sampatrilat. Sampatrilat may have potential for the treatment of hypertension and congestive heart failure. Phase II clinical studies are underway in the UK.